Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers
No Deal Was Announced, To The Chagrin Of Investors
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.
